相关临床试验
25
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
4.0%
已完成
11
44.0%
终止
10
40.0%
撤回
3
12.0%
暂无批准数据
- Baptist Health Hardin has become the first hospital globally to begin in-human clinical trials of Calidar Inc.'s revolutionary 4D Mammography system that uses X-ray diffraction to detect molecular-level tissue fingerprints. - The investigational technology aims to identify breast cancer earlier and more accurately by revealing tissue composition rather than just shape and density like traditional mammography. - The first-in-human study will enroll approximately 60 patients over several months to assess the system's potential to reduce unnecessary biopsies and improve diagnostic precision. - The 4D Mammography device measures how X-rays scatter at the molecular level to produce unique tissue signatures, offering a new dimension of diagnostic data not available with current imaging technology.
- InspireMD's CGuard Prime Carotid Stent System received FDA premarket approval based on the C-GUARDIANS pivotal trial showing the lowest 30-day (0.95%) and 1-year (1.93%) major adverse event rates of any carotid intervention study. - The device features proprietary MicroNet mesh technology that combines the largest open-cell frame with the smallest mesh pore size to prevent plaque protrusion and provide sustained embolic protection beyond five years. - The approval triggers a $17.9 million warrant tranche from InspireMD's $113.6 million financing agreement and enables immediate commercial launch in the United States following prior CE Mark approval in Europe. - The C-GUARDIANS trial enrolled 316 patients across 24 sites in the US and Europe, with 25% being symptomatic patients at high risk for carotid endarterectomy surgery.
• The phase 3 PROSTATE-IQ trial has enrolled its first patient, evaluating ArteraAI Prostate Test's ability to identify men who can safely reduce or avoid hormone therapy after prostatectomy. • The study will stratify patients with biochemical recurrence into risk groups, with low-risk patients receiving either 6 months of ADT or apalutamide monotherapy, while high-risk patients receive either 24 months of ADT or 6 months of ADT with apalutamide. • Led by Dr. Karen Elizabeth Hoffman from MD Anderson Cancer Center, the trial aims to improve quality of life by minimizing hormone therapy side effects while maintaining treatment efficacy across 11 clinical sites in the US.
